Pharmafile Logo

What next for the treatment of Psoriasis in Europe?

April 11, 2017 | PSP, psoriasis 

Research Director Laurent Chanroux investigates the changing market dynamics in Psoriasis in Europe.


Over the last decade, systemic biologic therapies for Psoriasis (PsO) have become widespread and the development of biological therapies has revolutionized the treatment of the disease. A chronic autoimmune disease, psoriasis has an estimated prevalence of 2.5% in Europe, representing approximately 15 million people, with 20–25% of these suffering from severe disease…

Read the article: https://www.researchpartnership.com/news/2017/03/article-what-next-for-the-treatment-of-psoriasis-in…

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Webcast:

UX beyond the website: Insights for the age of omnichannel

News:

MedTech Qualitative Specialist joins Research Partnership

Guide

How to embrace behavioural science principles in healthcare MR

Article

A glimmer of hope for Alzheimer’s patients, but at what cost?

Video

Virtual Conference Live

Report

Digital Health Tools - Physician Trends

Webcast

Oncology landscape: How innovative market research methods can navigate you to success

Article:

The disparity of patient experiences with Crohn’s Disease in Europe and Japan

Research Partnership’s MedTech Division appoints two Directors

Chris Carles has joined as a Director in our Philadelphia office and Andrew Way as a Research Director in our UK office.

Webcast: Influencing HCP behaviours – Is now the perfect opportunity?

Putting behavioural science at the forefront of market research